Study shows lower rate of inappropriate shocks in patients with Sorin dual chamber ICD devices
Denver, Colorado, USA, May 11, 2013 –Sorin Group, (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced findings from the landmark OPTION study1 demonstrating that patients with Sorin dual-chamber implantable cardioverter defibrillators (ICDs) experienced a significantly lower incidence of inappropriate shocks compared with patients with standard single-chamber devices (4.3% vs.10.3%, p=0.015).The study also found that there was no difference in all-cause mortality between the two groups.
The OPTION study ...